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Table 1. Demographic and clinical characteristics at hospital
admission of 29 patients with 36 episodes of suppurative
thrombophlebitis.
Variable Value
Age, median years (range) 33 (20–45)
Male sex, no. (%) of episodes 22 (61.1)
Chronic hepatitis C, no. (%) of episodes 30 (88.9)
HIV positivity, no. (%) of episodes 4 (11.1)
C-reactive protein level, median mg/dL (range) 162.5 (6–417)
Leukocyte count, median cells  109 (range) 12 (5.2–31)
Temperature, median C (range) 39.1 (35.3–41.3)
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Data about the required duration of intravenous therapy for
suppurative thrombophlebitis is lacking. Among 36 episodes
of proven suppurative thrombophlebitis requiring hospital
admission, no relapses occurred when treatment was given
for 17 days intravenously and followed by oral therapy. A
!4-week course of intravenous antibiotics may be sufficient.
Suppurative thrombophlebitis of proximal veins caused by non-
sterile injections is a potentially life-threatening condition that
is common among injection drug users (IDUs) [1]. In contrast
with catheter-related thrombophlebitis and Lemierre syndrome
[2, 3], little attention is paid to the antibiotic management of
suppurative thrombophlebitis [4]. Staphylococcus aureus is the
predominant bacteria in suppurative thrombophlebitis of IDUs
[5, 6]. In general, conservative antibiotic treatment is recom-
mended for suppurative thrombophlebitis of large veins [5, 6].
However, the duration and route of administration of antibiotic
treatment are uncertain, and experts recommend that therapy
be given according to published endocarditis-treatment guide-
lines [7]. However, a 4-week course of intravenous therapy is
often not feasible for IDUs [6]. A 2-week course of intravenous
therapy followed by oral ciprofloxacin plus rifampicin, admin-
istered according to the guidelines for treatment of right heart
endocarditis due to S. aureus in IDUs [8], seems to be an
alternative [6], but widespread use of this regimen may be
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difficult, because IDUs are frequently noncompliant to regi-
mens that require that they reliably take oral medications.
In a retrospective survey of infectious complications among
344 admissions of IDUs at our hospital (University Hospital
Basel; Basel, Switzerland), we diagnosed a suppurative throm-
bophlebitis in 36 cases (11%). In the present study, we analyze
the clinical course, duration of antibiotic therapy, and outcome
in these 36 cases of suppurative thrombophlebitis.
Methods. We included all IDUs who were hospitalized for
suppurative thrombophlebitis from January 2001 through De-
cember 2006 and evaluated by the infectious diseases service
of the University Hospital Basel, a 780-bed primary and tertiary
care center with ∼27,000 hospital admissions annually. De-
mographic and clinical data were extracted from hospital charts,
laboratory results, and separate reports of the infectious diseases
service. The study was approved by the ethics committee of
University Hospital Basel. The diagnosis of suppurative throm-
bophlebitis was defined by either 2 positive blood culture
results or bacteria detected in the thrombus in a patient with
negative blood culture results and detection of a thrombus by
CT or ultrasonography [3, 9].
Results. Thirty-six hospital admissions for suppurative
thrombophlebitis were identified among 29 IDUs (2 readmis-
sions to the hospital were considered to be relapses, and 5
readmissions were not). Patient characteristics at hospital ad-
mission are listed in table 1. Twenty-nine cases (80.6%) met
2 systemic inflammatory response syndrome criteria [10] at
hospital admission.
Thrombosis was detected on the basis of ultrasonographic
findings in 32 cases (89%) and on the basis of CT findings in
4 cases (11%). Transthoracic echocardiography was performed
in 31 (86%) of 36 cases; additional transesophageal echocar-
diography was performed in 5 of these 31 cases. Infective en-
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Table 2. Characteristics of suppurative thrombophlebitis.
Variable
No. (%)
of episodes
(n p 36)
Location
Femoral vein 21 (58.3)
Iliac vein 7 (19.4)
Great saphenous vein 2 (5.6)
Internal jugular vein 5 (13.9)
Subclavian vein 1 (2.8)
Predominant pathogena
Staphylococcus aureus 19 (52.8)
Streptococcus pyogenes 7 (19.4)
Viridans streptrococci 3 (8.3)
Streptococcus dysgalactiae 3 (8.3)
Streptococcus agalactiae 1 (2.8)
Peptostreptococcus asacharolyticus 2 (5.6)
Arcanobacterium hemolyticum 1 (2.8)
a Additional pathogens in polymicrobial infections were Fusobacterium nec-
rophorum, Micromonas micros, Actinomyces species, and Veillonella species.
docarditis was diagnosed in 3 cases. Because transthoracic echo-
cardiography cannot definitely rule out endocarditis, some cases
of infective endocarditis may have been missed.
Thromboses were located mainly in the femoral and the iliac
vein (table 2). The left side of the body was affected more
frequently (21 cases; 58.3%).
In 160 (71.4%) of a total of 224 blood samples obtained
within 48 h after hospital admission, the predominant pathogen
was cultured. In all but 10 cases,3 blood samples with positive
culture results were obtained. S. aureus was the most frequent
predominant pathogen (in 19 [53%] of the cases), followed by
streptococci (table 2). No methicillin-resistant S. aureus isolates
were identified. In 12 cases, polymicrobial sepsis was diagnosed.
In 1 case with negative blood culture results (in which only 1
pair of blood samples was obtained), a thrombectomy was
performed, and S. aureus was cultured from the biopsy spec-
imen. In all cases, intravenous antibiotic therapy was admin-
istered as first-line therapy. All but 1 case received b-lactam
antibiotics as the main antibiotic therapy (i.e., the antibiotic
given for the longest period intravenously) (table 3).
The duration of intravenous therapy varied greatly (table 3).
Four patients were treated for 7 days; 2 of these patients
experienced relapse leading to readmission (after 3 days and
after 5 days). There were no relapses among the patients who
were treated intravenously for 17 days. Six patients were treated
for 8–14 days, and 10 patients were treated for 15–21 days.
Altogether, in 20 (56%) of the episodes, the patients received
an intravenous therapy for 21 days. The median duration of
intravenous therapy was 19.5 days. In 9 cases, therapy was
continued 128 days because of additional complications. A
subsequent regimen of oral antibiotic therapy was administered
in 34 of 36 cases. The median duration of oral treatment was
9.5 days (range, 0–180 days), and the overall duration of an-
tibiotic therapy was a median of 28.5 days (range, 7–220 days).
There was no significant difference in the duration of intra-
venous therapy between patients treated for S. aureus infection
and those treated for non–S. aureus infection. Documented
negative blood culture results at day 3 of therapy did not in-
fluence the duration of intravenous antibiotic treatment (me-
dian duration of therapy was 22 days and 21.5 days for patients
with negative and patients with positive blood culture results,
respectively).
In 33 (91.7%) of the cases, anticoagulation therapy was ini-
tiated. In 10 cases (27.8%), oral anticoagulation therapy was
abandoned at hospital discharge because of compliance
concerns.
Additional complications associated with IDU were as fol-
lows: local skin abscesses in 14 cases (22.2%; incisions were
made in 8 cases); septic arthritis in 2 cases (5.6%; lavage was
necessary); 1 case of necrotizing fasciitis after suppurative
thrombophlebitis of the subclavian vein, resulting in amputa-
tion of the limb; 2 cases of acute osteomyelitis; 5 cases of
pulmonary abscesses; and 2 cases of empyemas. In addition to
these 11 cases that required surgical intervention because of
additional complications, only 1 case involved a patient who
underwent surgery of the involved vein; this patient experi-
enced a local abscess formation that required excision of the
internal jugular vein.
The median duration of hospitalization was 20 days (range,
6–58 days), and the median time to defervescence was 2 days
(range, 0–17 days). Negative blood culture results were obtained
at follow-up in 28 cases (77.8%). The median time from start
of therapy to the first negative blood culture result was 4.5 days
(range, 2–167 days).
The overall readmission rate was high (table 4). However,
only 2 readmissions were attributable to relapses of suppurative
thrombophlebitis. According to the death records of the local
authorities, no patient died after hospital discharge.
Discussion. Suppurative thrombophlebitis is a potentially
dangerous complication in IDUs. No studies or clinical trials
have investigated the optimal duration of intravenous antibiotic
treatment. Four weeks of therapy is recommended according
to expert opinions [7]. A long hospital stay for intravenous
therapy may not be feasible because of compliance and ad-
herence problems in IDUs [11]. In our study, the intravenous
antibiotic treatment duration was quite variable, ranging from
!7 days to 128 days. No relapse occurred in cases treated in-
travenously for 17 days. In more than one-half of the episodes
(20 episodes; 56%), the patient received intravenous therapy
for21 days. The present data suggests that a 2–3-week course
of intravenous therapy followed by therapy with oral antibiotics
was safe for suppurative thrombophlebitis. Adherence in IDUs
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Table 3. Therapy for suppurative thrombophlebitis.
Variable
Suppurative
thrombophlebitis
episodes
(n p 36)
Main antibiotica
Amoxicillin-clavulanate 12 (33.3)
Penicillin 12 (33.3)
Flucloxacillin 9 (25.0)
Piperacillin-tazaobactam 1 (2.8)
Imipenem-cilastatin 1 (2.8)
Vancomycin 1 (2.8)
Duration of intravenous therapy
Overall
Median days (range) 19.5 (6–85)
7 Days 4 (11.1)
8–14 Days 6 (16.7)
15–21 Days 10 (27.8)
22–28 Days 7 (19.4)
128 Days 9 (25)
For Staphylococcus aureus infectionb
No. of episodes 19
Median days (range) 23 (6–85)
For non–S. aureus infectionb
No. of episodes 17
Median days (range) 18 (7–41)
Duration of oral therapy, median days (range) 9.5 (0–180)
NOTE. Data are no. (%) of episodes, unless otherwise indicated.
a Main antibiotic was considered to be the antibiotic given for the longest
period intravenously.
b for differences between groups, using 2-tailed Mann-WhitneyPp .837
U test.
Table 4. Outcome of suppurative thrombophlebitis.
Variable
No. (%)
of episodes
(n p 36)
Negative blood culture results
Available 28 (77.8)
Obtained during therapy 23 (63.9)
Hospital readmission
Overall 28 (77.8)
Relapse 2 (5.6)
is known to be limited. Therefore, it remains uncertain whether
the oral medications were taken.
Two or more systemic inflammatory response syndrome cri-
teria [10] were met by 29 cases (80.6%) at hospital admission,
emphasizing the severity of illness and confirming that IDUs
tend to present late in the course of illness. In accordance with
the literature, we found no attributable mortality. A recent
review involving 115 patients showed a mortality rate of !2%
[4].
We identified S. aureus as the pathogen most frequently cul-
tured, which is in accordance with the findings of other studies
[5]. S. aureus is one of the most frequently isolated pathogens
in infective right-heart endocarditis among IDUs [8]. There-
fore, empirical therapy for IDUs with suspected suppurative
thrombophlebitis or infective endocarditis should cover this
pathogen. In our region, methicillin-resistant S. aureus is rare
[12]; therefore, empirical treatment with amoxicillin-clavulan-
ate or flucloxacillin is sufficient.
Most septic thromboses were identified in veins of the lower
limbs (83.3%). This might be explained by the use of less hy-
gienic injection techniques when injecting in the lower limbs,
compared with injection techniques used in the upper limbs.
Only 1 suppurative thrombophlebitis was identified in the up-
per subclavian vein, which may reflect metastatic infection.
An excision of the vein was performed in only 1 patient who
presented with an abscess formation. The other 35 cases were
successfully treated with antibiotic and anticoagulation therapy.
In the literature, conservative management is proposed for sup-
purative thrombophlebitis of large veins, whereas the failure of
conservative therapy and catheter-related or suppurative
thrombophlebitis of small peripheral veins are indications for
surgical intervention [5, 6].
Our data are not sufficient to make a recommendation con-
cerning anticoagulation in IDUs with suppurative thrombo-
phlebitis, which is still under discussion. A recently published
systematic review showed that there is a lack of comparative
trials studying the effectiveness and toxicity of heparin in pa-
tients with suppurative thrombophlebitis [4]. In our study, all
but 3 patients received anticoagulation therapy during hospi-
talization; the 3 patients who did not receive anticoagulation
therapy received low–molecular weight heparin in prophylactic
doses.
A limitation of our study is the use of a retrospective analysis
with a limited number of cases. Nevertheless, our study is, to
our knowledge, the largest case series reported to date. A further
strength of our study is the exact information about outcome
parameters: IDUs in our area are not likely to be admitted to
any other hospitals, and death records from local authorities
were available, precluding the possibility that any deaths oc-
curred as consequences of relapses without our knowledge.
Also, it is extremely unlikely that we have missed any IDUs
with suppurative thrombophlebitis during the observation pe-
riod in our hospital, because the infectious diseases service
evaluates all patients with positive blood culture results. There-
fore, any selection bias is unlikely.
The present data suggest that suppurative thrombophlebitis
could be sufficiently treated with an intravenous antibiotic
course of 14–21 days followed by oral therapy. This observation
should be evaluated in a prospective randomized study com-
paring short regimens versus longer regimens.
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